Scarica l'app Stockscreener
2.5604
5.69%
-0.1546
Cosciens Biopharma Inc Borsa (CSCI) Ultime notizie
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - MarketScreener
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Reports - StockTitan
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - The Manila Times
COSCIENS Biopharma Inc. Announces Potential Delay in Annual Financial Filing Due to Audit Complexities - Nasdaq
Cosciens Biopharma announces possible delay in filing 2024-end documents - TipRanks
Material Control Issues Force COSCIENS to Delay Critical Financial Filings Until Q2 - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last We - Asianet Newsable
1 Growth Stock Down 45% to Buy Right Now, According to Wall Street - The Globe and Mail
COSCIENS advances to Phase 2a study for inflammation treatment By Investing.com - Investing.com Australia
CSCI stock touches 52-week low at $2.28 amid market challenges - Investing.com
CSCI stock touches 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial - TipRanks
COSCIENS advances to Phase 2a study for inflammation treatment - Investing.com India
Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate -March 13, 2025 at 08:21 am EDT - Marketscreener.com
Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy - Marketscreener.com
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - The Manila Times
COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results - Nasdaq
Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides - TipRanks
COSCIENS Phase 1 Trial Hits All Safety Marks, Phase 2a Launch Set for Novel Anti-Inflammatory Drug - Stock Titan
Septerna pulls lead hypoparathyroidism drug on bilirubin levels - BioWorld Online
COSCIENS Biopharma halts investment in macimorelin; CMO to depart - Seeking Alpha
COSCIENS Biopharma Focuses on Natural Product Growth - TipRanks
Cosciens Biopharma provides update, reiterates pipeline prioritization - TipRanks
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewswire
COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline - StockTitan
CSCI stock touches 52-week low at $2.61 amid market challenges - Investing.com Australia
CSCI stock touches 52-week low at $2.61 amid market challenges By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
This Biopharma Stock Could Be 2025’s Biggest Comeback Story - Wealth Awesome
Aeterna Zentaris : to Present at Upcoming Biotech Showcase Conference in San Francisco - Marketscreener.com
CSCI stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
CSCI stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - The Pioneer
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):